We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

By LabMedica International staff writers
Posted on 07 Oct 2015
Print article
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).
Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness. The findings are especially relevant for drugs designated by the US Food and Drug Administration (FDA) as meeting certain criteria.

In everyday usage, the term “breakthrough” represents a highly significant or definitive advance. However, since the FDA Safety and Innovation Act became law in 2012, the FDA can assign the breakthrough designation to a drug that “treats a serious or life-threatening condition” and “may demonstrate a substantial improvement…over available therapies” – based only on preliminary evidence. Such drugs often receive “accelerated approval.” Since the Safety and Innovation Act, all FDA press releases (PRs) announcing approval of a breakthrough-designated drug have used the term “breakthrough” and about half use “promising.”

Researchers from Carnegie Mellon University (Pittsburgh, PA, USA) and The Dartmouth Institute for Health Policy and Clinical Practice (Hanover, NH, USA) studied how catchphrase terms affect public perception of a new drug. “Today, patients and their families can easily find FDA PRs on the internet, or they often hear about them in the news,” said Prof. Woloshin, Dartmouth Institute, “But the reality is that unless patients fully understand how the FDA is using the term ‘breakthrough,’ they may have unwarranted confidence in the evidence supporting drug claims. So, we thought it was important to test how these terms affect the judgment of people without medical training.”

Participants in the online study were randomly given one of various short descriptions of a recently approved drug. The descriptions were based on an FDA PR for a metastatic lung cancer breakthrough-designated drug, conditionally approved based on the surrogate outcome tumor shrinkage. The facts-only description described the drug as meeting the breakthrough-criteria, but did not use the term “breakthrough.” A second and a third description added the terms “breakthrough” and “promising” respectively. A fourth, classified as “tentative,” used FDA-required language for professional labeling. Another, classified as “definitive,” changed the phrasing from “may be contingent” to “is contingent.” Participants were then asked to judge the drug’s benefit, harm, and strength of evidence.

Adding either “breakthrough” or “promising” in the description very significantly increased the percentage of participants who rated the drug as “very” or “completely” effective compared with the facts-only description (23% and 25% vs. 11%); it also significantly increased the number of people who reported believing that evidence supporting the drug is “strong” or “extremely strong” (59% and 63% vs. 43%). The tentative and definitive descriptions significantly reduced the percentage who believed (incorrectly) that the drug was “proven to save lives” (16%-tentative and 10%-definitive vs. 31%-breakthrough).

When participants were asked which of two drugs—one described as “breakthrough,” the other as meeting the breakthrough criteria—they would take for a potentially deadly condition, 92% chose the “breakthrough” drug.

“Our findings clearly indicate that words like ‘breakthrough’ and ‘promising’ increase people’s belief in a drug’s effectiveness (sometimes incorrectly),” said Prof. Schwartz, Dartmouth Institute, “PRs with neutral terms and that clearly explain the limited evidence supporting what breakthrough-designation and accelerated-approval mean might help consumers make more accurate judgments.”

The study, by Krishnamurti T et al., was published online September 21, 2015, in the journal JAMA Internal Medicine.

Related Links:

Carnegie Mellon University
The Dartmouth Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.